NCT07642076

Brief Summary

This study aims to evaluate the possible efficacy of l-carnitine in critically ill hepatic patients admitted to intensive care unit.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for phase_4

Timeline
9mo left

Started Jun 2026

Shorter than P25 for phase_4

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
Jun 2026Mar 2027

Study Start

First participant enrolled

June 1, 2026

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

June 2, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 11, 2026

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2027

Last Updated

June 11, 2026

Status Verified

June 1, 2026

Enrollment Period

6 months

First QC Date

June 2, 2026

Last Update Submit

June 7, 2026

Conditions

Hepatic

Outcome Measures

Primary Outcomes (6)

  • laboratory value: serum creatinine(SCr)

    At ICU admission and at ICU discharge, an average of 7 days

  • laboratory value: international normalized ratio

    At ICU admission and at ICU discharge, an average of 7 days

  • laboratory value: Blood urea nitrogen(BUN)

    At ICU admission and at ICU discharge, an average of 7 days

  • laboratory value: Albumin

    At ICU admission and at ICU discharge, an average of 7 days

  • laboratory value: Alanine aminotransferase(ALT)

    At ICU admission and at ICU discharge, an average of 7 days

  • laboratory value: Aspartate aminotransferase(AST)

    At ICU admission and at ICU discharge, an average of 7 days

Other Outcomes (1)

  • • hospitalization stay in ICU

    At ICU admission and at ICU discharge, an average of 7 days

Study Arms (2)

control group

ACTIVE COMPARATOR
Drug: Standard medical treatment

test group

ACTIVE COMPARATOR

l carnitine

Drug: L CarnitineDrug: Standard medical treatment

Interventions

L CarnitineDRUG

L-Carnitine, a natural substance present in the body, is essential for energy metabolism in mammals. l-carnitine presents as a drug.

test group
Standard medical treatmentDRUG

Standard medical treatment for hepatic patient admitted to icu

control grouptest group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age more than 18 years old
  • male or female with confirmed liver disease admitted to intensive care unit, including:
  • Acute-on-chronic liver failure (ACLF)
  • Hepatic encephalopathy
  • spontaneous bacterial peritonitis (SBP)
  • variceal bleeding
  • fulminant hepatitis
  • Hepatorenal syndrome
  • Ascites
  • Etc

You may not qualify if:

  • Age of less than 18 years old
  • Pregnancy or Lactation
  • patients have seizure
  • patient on warfarin

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Carnitine

Intervention Hierarchy (Ancestors)

Trimethyl Ammonium CompoundsQuaternary Ammonium CompoundsAminesOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 2, 2026

First Posted

June 11, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

March 1, 2027

Last Updated

June 11, 2026

Record last verified: 2026-06